Physician profile
Joseph Walker
NPI 1396866943
$3,340.31
in general payments reported to CMS, 2019-2025
27 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $261 · 2021: $565 · 2022: $804 · 2023: $669 · 2024: $588 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,143.93 | 2021-2025 | Puraply, Novachor, Via Matrix |
| Novo Nordisk INC | $689.73 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $278.57 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $224.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Genzyme Corporation | $145.50 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $129.81 | 2020-2023 | Seglentis, Livalo |
| Elucent Medical | $105.14 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $93.63 | 2021-2023 | Dupixent |
| Eisai INC. | $80.19 | 2020-2021 | |
| Lilly USA, LLC | $72.84 | 2022-2024 | Zepbound |
| Novartis Pharmaceuticals Corporation | $42.74 | 2022-2023 | |
| Amgen INC. | $39.39 | 2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $31.21 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.95 | 2023 | Rexulti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $23.90 | 2025 | Auvelity |
| Averitas Pharma INC. | $22.42 | 2025 | Qutenza |
| Pfizer INC. | $20.70 | 2023 | |
| Almatica Pharma LLC | $20.42 | 2021 | |
| Merz North America, INC. | $20.18 | 2021 | |
| Exact Sciences Corporation | $15.96 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2020 | |
| Janssen Biotech, INC. | $14.31 | 2024 | Simponi Aria, Simponi, Stelara |
| Ucb, INC. | $13.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.80 | 2019 | |
| Abbvie INC. | $11.07 | 2021 | |
| Merck Sharp & Dohme LLC | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.